Pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal anti-SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase IIa study
Benjamin Gaborit, Eric Dailly, Bernard Vanhove, Régis Josien, Karine Lacombe, Vincent Dubee, Virginie Ferre, Sophie Brouard, Florence Ader, Marie-Anne Vibet, Aurélie Le Thuaut, Richard Danger, Laurent Flet, Anne Omnes, Laetitia Berly, Anne Chiffoleau, Alexandra Jobert, Odile Duvaux, François Raffi, POLYCOR trial group
doi: https://doi.org/10.1101/2021.04.15.21255549
Benjamin Gaborit
1Department of Infectious Disease, Nantes University Hospital, Nantes, France
2INSERM CIC1413, Nantes University Hospital and Inserm, Nantes, France
Eric Dailly
3Clinical Pharmacology Department, CHU Nantes, Nantes, France
Bernard Vanhove
4Xenothera, Nantes, France
Régis Josien
5Centre de Recherche en Transplantation et Immunologie UMR 1064, INSERM, Université de Nantes, ITUN, CHU Nantes, Nantes, France
6Laboratoire d’Immunologie, CIMNA,CHU Nantes, Nantes, France
Karine Lacombe
7Institut Pierre Louis d’Epidémiologie et de Santé Publique, Sorbonne Université, INSERM, AP-HP, Hôpital Saint-Antoine, Service des Maladies Infectieuses et Tropicales, Paris, France
Vincent Dubee
8Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire d’Angers, Angers
Virginie Ferre
2INSERM CIC1413, Nantes University Hospital and Inserm, Nantes, France
9Virology Laboratory University Hospital, Nantes France
Sophie Brouard
6Laboratoire d’Immunologie, CIMNA,CHU Nantes, Nantes, France
Florence Ader
10Centre International de Recherche en Infectiologie (CIRI), Inserm 1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, F-69007 Lyon, France
Marie-Anne Vibet
12CHU Nantes, Sponsor Department, Nantes, France
Aurélie Le Thuaut
12CHU Nantes, Sponsor Department, Nantes, France
Richard Danger
6Laboratoire d’Immunologie, CIMNA,CHU Nantes, Nantes, France
Laurent Flet
13CHU Nantes, Pharmacy Department, Nantes, France
Anne Omnes
12CHU Nantes, Sponsor Department, Nantes, France
Laetitia Berly
12CHU Nantes, Sponsor Department, Nantes, France
Anne Chiffoleau
12CHU Nantes, Sponsor Department, Nantes, France
Alexandra Jobert
12CHU Nantes, Sponsor Department, Nantes, France
Odile Duvaux
4Xenothera, Nantes, France
François Raffi
1Department of Infectious Disease, Nantes University Hospital, Nantes, France
2INSERM CIC1413, Nantes University Hospital and Inserm, Nantes, France
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
The data analysed and presented in this study are available from the corresponding author on reasonable request, providing the request meets local ethical and research governance criteria after publication. Data collected during the study may be processed electronically, in accordance with the requirements of the CNIL (compliance with reference methodology MR001).
Posted April 20, 2021.
Pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal anti-SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase IIa study
Benjamin Gaborit, Eric Dailly, Bernard Vanhove, Régis Josien, Karine Lacombe, Vincent Dubee, Virginie Ferre, Sophie Brouard, Florence Ader, Marie-Anne Vibet, Aurélie Le Thuaut, Richard Danger, Laurent Flet, Anne Omnes, Laetitia Berly, Anne Chiffoleau, Alexandra Jobert, Odile Duvaux, François Raffi, POLYCOR trial group
medRxiv 2021.04.15.21255549; doi: https://doi.org/10.1101/2021.04.15.21255549
Pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal anti-SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase IIa study
Benjamin Gaborit, Eric Dailly, Bernard Vanhove, Régis Josien, Karine Lacombe, Vincent Dubee, Virginie Ferre, Sophie Brouard, Florence Ader, Marie-Anne Vibet, Aurélie Le Thuaut, Richard Danger, Laurent Flet, Anne Omnes, Laetitia Berly, Anne Chiffoleau, Alexandra Jobert, Odile Duvaux, François Raffi, POLYCOR trial group
medRxiv 2021.04.15.21255549; doi: https://doi.org/10.1101/2021.04.15.21255549
Subject Area
Subject Areas
- Addiction Medicine (346)
- Allergy and Immunology (666)
- Anesthesia (181)
- Cardiovascular Medicine (2636)
- Dermatology (223)
- Emergency Medicine (398)
- Epidemiology (12206)
- Forensic Medicine (10)
- Gastroenterology (756)
- Genetic and Genomic Medicine (4081)
- Geriatric Medicine (387)
- Health Economics (679)
- Health Informatics (2639)
- Health Policy (1002)
- Hematology (362)
- HIV/AIDS (849)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (433)
- Neurology (3861)
- Nursing (209)
- Nutrition (575)
- Oncology (2017)
- Ophthalmology (584)
- Orthopedics (240)
- Otolaryngology (304)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (472)
- Pediatrics (1113)
- Primary Care Research (450)
- Public and Global Health (6512)
- Radiology and Imaging (1396)
- Respiratory Medicine (871)
- Rheumatology (403)
- Sports Medicine (342)
- Surgery (442)
- Toxicology (52)
- Transplantation (185)
- Urology (165)